| CAS NO: | 111540-00-2 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 2mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| Molecular Weight (MW) | 306.31 |
|---|---|
| Formula | C19H14O4 |
| CAS No. | 111540-00-2 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 10 mg/mL |
| Water: <1 mg/mL | |
| Ethanol: N/A | |
| Other info | Chemical Name:
8-hydroxy-3-methyl-3,4-dihydrotetraphene-1,7,12(2H)-trione InChi Key: ZAWXOCUFQSQDJS-UHFFFAOYSA-N InChi Code: InChI=1S/C19H14O4/c1-9-7-10-5-6-12-17(15(10)14(21)8-9)19(23)11-3-2-4-13(20)16(11)18(12)22/h2-6,9,20H,7-8H2,1H3 SMILES Code: O=C1CC(C)CC2=CC=C3C(C(C4=CC=CC(O)=C4C3=O)=O)=C12 |
| Synonyms | NSC-628869; STA21; NSC 628869; STA21; NSC628869; STA 21; Ochromycinone. |
| In Vitro | In vitro activity: In vitro study showed that, in both mouse and human CD4+ T cells, the treatment with STA-21 could induce the expression of FoxP3 and repressed IL-17 expression. In addition, STA-21 was able to prevent both human monocytes and mouse BMM cells from differentiating into osteoclasts. Cell Assay: Human breast cancer cell lines MDA-MB-231, MDA-MB-435s, MDA-MB-453, MDA-MB-468, and MCF7, human ovarian carcinoma cell line Caov-3, and human skin fibroblasts were cultured in DMEM containing 10% FBS and appropriate antibiotics in a 5% CO2 incubator at 37°C. For testing different compounds, the cells were exposed to the compounds for 48 h at a final concentration of 20 or 30 μM, respectively. Then, the cells were harvested and subjected to flow-cytometry analysis. |
|---|---|
| In Vivo | In previous animal study, IL-1Ra-KO mice were treated with i.p. injections of STA-21 at 0.5 mg/kg 3 times per week for 3 weeks. Results showed that STA-21 could suppress inflammatory arthritis in IL-1Ra-KO mice. The Th17 cell proportion decreased and the proportion of Treg cells expressing FoxP3 was increased in the spleens of STA-21-treated mice markedly. Moreover, the adoptive transfer of CD4+CD25+ T cells from STA-21-treated IL-1Ra-KO mice suppressed inflammatory arthritis markedly. |
| Animal model | IL-1Ra–KO mice |
| Formulation & Dosage | Dissolved in saline; 0.5 mg/kg; i.p. injection |
| References | Proc Natl Acad Sci U S A. 2005 Mar 29;102(13):4700-5; BMC Cancer. 2007 Jun 28;7:111; Arthritis Rheumatol. 2014 Apr;66(4):918-29. |
m.cnreagent.com